The differential sensitivity of these AML cell lines to LDN-193189 together with the BMP4-induced expression of MIXL1 suggests that inhibition of the BMP receptor kinase may be an effective therapeutic approach for MIXL1 expressing AML cells. Here, MIXL1 is linked to acute myeloid leukemia.